Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: A phase II randomised study

European Respiratory Journal

Volumn 41, Issue 5, 2013, Pages 1107-1115

  Wilson, Robert ^a   Welte, Tobias ^c   Polverino, Eva ^e   De Soyza, Anthony ^b   Greville, Hugh ^f   O'Donnell, Anne ^g   Alder, Jeff ^h   Reimnitz, Peter ^d   Hampel, Barbara ^d  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d BAYER PHARMA AG   (Germany)

^e INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^f ROYAL ADELAIDE HOSPITAL   (Australia)

^g GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^h Bayer HealthCare Pharmaceuticals Inc   (United States)

Author keywords

Antibiotic; Bacteria; Chronic lung infection; Exacerbation; Inflammation; Pseudomonas aeruginosa

Indexed keywords

C REACTIVE PROTEIN; CIPROFLOXACIN; PLACEBO;

ADULT; ARTICLE; BACTERIAL COUNT; BACTERIAL LOAD; BACTERIUM ISOLATION; BRONCHIECTASIS; BRONCHOSPASM; COLONY FORMING UNIT; COMPLEX REGIONAL PAIN SYNDROME; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY POWDER; DYSGEUSIA; FEMALE; FOLLOW UP; HAEMOPHILUS INFLUENZAE; HALLUCINATION; HEMOPTYSIS; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MULTICENTER STUDY; NEUTROPHIL COUNT; PATHOGEN CLEARANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; SEPSIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIBIOTIC; BACTERIA; CHRONIC LUNG INFECTION; EXACERBATION; INFLAMMATION; PSEUDOMONAS AERUGINOSA;

ADMINISTRATION, INHALATION; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; BRONCHIECTASIS; CIPROFLOXACIN; COLONY COUNT, MICROBIAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRY POWDER INHALERS; FEMALE; HUMANS; INFLAMMATION; LUNG DISEASES; MALE; MIDDLE AGED; POWDERS; PSEUDOMONAS AERUGINOSA; TREATMENT OUTCOME;

EID: 84877093743     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00071312     Document Type: Article

References (26)

1. Seitz AE, Olivier KN, Adjemian J, et al. Trends in bronchiectasis among Medicare beneficiaries in the United States, 2000-2007. Chest 2012; 142: 432-439.
2. Loebinger MR, Wells AU, Hansell DM, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009; 34: 843-849.
3. Angrill J, Agusti C, de Celis R, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002; 57: 15-19. (Pubitemid 34081538)
4. Smith MP. Non-cystic fibrosis bronchiectasis. J R Coll Physicians Edinb 2011; 41: 132-139.
5. King PT. The pathophysiology of bronchiectasis. Int J Chron Obstruct Pulmon Dis 2009; 4: 411-419.
6. O'Donnell AE. Bronchiectasis. Chest 2008; 134: 815-823.
7. Hill AT, Pasteur M, Cornford C, et al. Primary care summary of the British Thoracic Society Guideline on the management of noncystic fibrosis bronchiectasis. Prim Care Respir J 2011; 20: 135-140.
8. Rubin BK. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. J Aerosol Med Pulm Drug Deliv 2008; 21: 71-76.
9. Woodhead M. New guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2011; 38: 1250-1251.
10. Chalkley LJ, Koornhof HJ. Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions. Antimicrob Agents Chemother 1985; 28: 331-342. (Pubitemid 15019972)
11. Gupta A, Tarara T, Miller D, et al. A novel high-payload dry powder formulation of ciprofloxacin for management of chronic lung infections. Am Assoc Pharmaceut Scientists J 2011; 13(S2): abstract R6156.
12. Stass H, Baumann-Noss S, Delesen H, et al. Ciprofloxacin PulmoSphere1 inhalational powder: a healthy volunteer study. Am J Respir Crit Care Med 2008; 177: G50.
13. Stass H, Ludwig M, Nagelschmitz J, et al. Safety and pharmacokinetics of inhaled dry powder ciprofloxacin after single and multiple inhalations in adult patients with cystic fibrosis. Paediatr Pulmonol 2008; 43(S31): abstract 282, p. 300.
14. Tokimatsu I, Hiramatsu K, Morimoto T, et al. Safety, tolerability and pharmacokinetics of ciprofloxacin dry powder for inhalation in patients with mild to moderate chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2011; 183: A3105.
15. Wilson CB, Jones PW, O'Leary CJ, et al. Validation of the St. George's Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med 1997; 156: 536-541. (Pubitemid 27351991)
16. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321-1327.
17. Hester KL, Macfarlane JG, Tedd H, et al. Fatigue in bronchiectasis. QJM 2012; 105: 235-240.
18. Murray MP, Govan JR, Doherty CJ, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011; 183: 491-499.
19. Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000; 162: 1277-1284.
20. Shoemark A, Ozerovitch L, Wilson R. Aetiology in adult patients with bronchiectasis. Respir Med 2007; 101: 1163-1170. (Pubitemid 46667677)
21. Stockley RA, Bayley D, Hill SL, et al. Assessment of airway neutrophils by sputum colour: correlation with airways inflammation. Thorax 2001; 56: 366-372. (Pubitemid 32398127)
22. Fiel SB. Aerosolized antibiotics in cystic fibrosis: current and future trends. Expert Rev Respir Med 2008; 2: 479-487.
23. LiPuma JJ. Microbiological and immunologic considerations with aerosolized drug delivery. Chest 2001; 120: 118S-123S.
24. Jones PW. St. George's Respiratory Questionnaire: MCID. COPD 2005; 2: 75-79.
25. Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007; 132: 1565-1572. (Pubitemid 350156014)
26. Ryan G, Singh M, Dwan K. Inhaled antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst Rev 2011; 3: CD001021.